KaydedilenlerDerginizi ekleyin

Dergiler / Journal of Turkish Spinal Surgery / 2021 / Cilt: 32 - Sayı: 1

FUNCTIONAL RECOVERY AFTER WHARTON’S JELLY–DERIVED MESENCHYMAL STEM CELL ADMINISTRATION IN A PATIENT WITH TRAUMATIC SPINAL CORD INJURY: A PILOT STUDY

Serdar KABATAŞ
Serdar KABATAŞ
Eyup Can SAVRUNLU
Necati KAPLAN
Ercan CETIN
Furkan DİREN
Osman BOYALI
Göksel GÜVEN
Erdal KARAÖZ
Sayfa
38–46
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

After stem cell infusions, progressive improvements were shown in the patient’s neurological examination and neurophysiological and neuroradiological findings.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The use of stem cells in the treatment of traumatic spinal cord injury (SCI) in recent years has provided promising results.
📊
Temel Bulgular & Veri:Here, we reported on a 29-year-old man who was treated with WJ-MSCs in the course of therapy for blunt, traumatic SCI due to a work accident.
💡
Sonuç & Katkı:After stem cell infusions, progressive improvements were shown in the patient’s neurological examination and neurophysiological and neuroradiological findings.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

The use of stem cells in the treatment of traumatic spinal cord injury (SCI) in recent years has provided promising results. Different sources of cells for transplantation have been used, including mesenchymal stem cells [MSCs; e.g., Wharton’s jelly-derived (MSCs WJ-MSCs)]. Here, we reported on a 29-year-old man who was treated with WJ-MSCs in the course of therapy for blunt, traumatic SCI due to a work accident. He was operated on within 6 hours of the injury. Three and a half months later, he underwent intrathecal, intramuscular, and intravenous administrations of WJ-MSCs at a target dose of 1x106/kg for each application route (twice a month for 2 months). All the procedures were tolerated well by the patient. In parallel to this, we have not seen any application-related complications so far. After stem cell infusions, progressive improvements were shown in the patient’s neurological examination and neurophysiological and neuroradiological findings.

🔖

Bu Makaleye Atıf Yap

KABATAŞ, S., KABATAŞ, S., SAVRUNLU, E. C., KAPLAN, N., CETIN, E., DİREN, F., BOYALI, O., GÜVEN, G., KARAÖZ, E. (2021). FUNCTIONAL RECOVERY AFTER WHARTON’S JELLY–DERIVED MESENCHYMAL STEM CELL ADMINISTRATION IN A PATIENT WITH TRAUMATIC SPINAL CORD INJURY: A PILOT STUDY. Journal of Turkish Spinal Surgery, Cilt: 32 - Sayı: 1, 38–46. https://ajindex.com/articles/270675

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Devivo MJ. Epidemiology of traumatic spinal cord injury: trends and future implications. Spinal Cord. 2012;50:365-72
  2. Kim YH, Ha KY, Kim SI. Spinal cord injury and related clinical trials. Clin Orthop Surg. 2017;9:1-9
  3. Sekhon LH, Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine (Phila Pa 1976). 2001;26(24 Suppl):2-12
  4. Bramlett HM, Dietrich WD. Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies. Prog Brain Res. 2007;161:125-41
  5. Park E, Velumian AA, Fehlings MG. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for White matter degeneration. J Neurotrauma. 2004;21:754-74
  6. Gholaminejhad M, Arabzadeh S, Akbari M, Mohamadi Y, Hassanzadeh G. Anti-oxidative and neuroprotective effects of flaxseed on experimental unilateral spinal cord injury in rat. J Contemp Med Sci. 2017;3:213-7
  7. Ijaz S, Mohammed I, Gholaminejhad M, Mokhtari T, Akbari M, Hassanzadeh G. Modulating pro-inflammatory cytokines, tissue damage magnitude, and motor deficit in spinal cord injury with subventricular zone-derived extracellular vesicles. J Mol Neurosci. 2020;70:458-66
  8. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev. 2012;1:CD001046
  9. Karaoz E, Tepekoy F, Yilmaz I, Subasi C, Kabatas S. Reduction of ınflammation and enhancement of motility after pancreatic ıslet derived stem cell transplantation following spinal cord ınjury. J Korean Neurosurg Soc. 2019;62:153-65
  10. Kabataş S, Civelek E, İnci Ç, Yalçınkaya EY, Günel G, Kır G, et al. Wharton’s jelly-derived mesenchymal stem cell transplantation in a patient with hypoxic-ischemic encephalopathy: a pilot study. Cell Transplant. 2018;27:1425-33
  11. Okur SÇ, Erdoğan S, Demir CS, Günel G, Karaöz E. The effect of umbilical cord-derived mesenchymal stem cell transplantation in a patient with cerebral palsy: a case report. Int J Stem Cells. 2018;11:141-7
  12. Huang H, Young W, Chen L, Feng S, Zoubi ZMA, Sharma HS, et al. Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2017). Cell Transplant. 2018;27:310-24
  13. Osunronbi T, Sharma H. International standards for neurological classification of spinal cord injury: factors influencing the frequency, completion and accuracy of documentation of neurology for patients with traumatic spinal cord injuries. Eur J Orthop Surg Traumatol. 2019;29:1639-48
  14. Thorpe ER, Garrett